Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

This study suggests that statins may help treat acute alopecia areata, with animal experiments showing increased regulatory T cell populations after statin treatment in mice with the condition.

This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.

This review discusses the development of Janus kinase inhibitors for dermatologic diseases and reports no new results; the authors note the need for further research on their efficacy and safety.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Stem cells compete for space using cell adhesion, and mutations can affect their competitive success, with implications for tissue health and disease.

In this study, hair follicle transcriptomic responses to a 10-day HIIT program revealed both existing and new biomarkers, such as certain miRNAs, offering a potentially effective way to monitor cellular and molecular HIIT adaptations.

This study found that mesenchymal stem cell treatment alleviated atopic dermatitis-like symptoms in a mouse model by modulating immune and inflammatory responses, with gene expression changes suggesting pathways for potential personalized treatment approaches.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

This study identified key proteins, such as Sfrp1 and Ppard, involved in the complex and dynamic regulation of yak hair follicle growth and degeneration across different stages, offering insights into yaks' adaptation to highland environments.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This review discusses factors affecting hair health, types of alopecia, and the potential of phytochemicals in managing hair loss but reports no new clinical results; it highlights the need for further studies.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This review highlights the potential of natural compounds like terpenoids, flavonoids, and polyphenols in promoting hair regrowth for those with alopecia areata by activating growth pathways and modulating immune responses, but calls for further research to confirm their therapeutic utility.

This study suggests that phytochemicals from natural sources could be safer alternatives to conventional treatments for hair loss, as they may activate key pathways involved in hair growth.

This review examines the pathophysiological mechanisms and emerging targeted treatments for alopecia areata, particularly highlighting the efficacy of oral JAK inhibitors over other less effective alternatives.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

Leflunomide is more likely to help treat alopecia areata than cause it.

This meeting synopsis on the 66th Annual Montagna Symposium reports no new results but outlines discussions on precision dermatology, integrating molecular insights with clinical applications for personalized skin care.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.

This review discusses current and emerging treatments for discoid lupus erythematosus, suggesting that new biologic and small-molecule therapies may improve disease control when combined with traditional management.

This study concluded that advancements in understanding the immunological mechanisms of alopecia areata have led to promising therapies, particularly JAK inhibitors and novel drug delivery systems, but further research is needed for clinical application.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.